Eleven Biotherapeutics, Inc. (EBIO) EPS Estimated At $-0.13; Vse Has 1.44 Sentiment

April 17, 2018 - By Richard Conner

Analysts expect Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) to report $-0.13 EPS on May, 3.They anticipate $0.12 EPS change or 48.00% from last quarter’s $-0.25 EPS. After having $-0.22 EPS previously, Eleven Biotherapeutics, Inc.’s analysts see -40.91% EPS growth. The stock decreased 2.82% or $0.0446 during the last trading session, reaching $1.5354. About 630,313 shares traded. Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) has declined 52.78% since April 17, 2017 and is downtrending. It has underperformed by 64.33% the S&P500.

Vse Corp (VSEC) investors sentiment decreased to 1.44 in Q4 2017. It’s down -0.39, from 1.83 in 2017Q3. The ratio is negative, as 52 hedge funds opened new or increased positions, while 36 cut down and sold their equity positions in Vse Corp. The hedge funds in our database now own: 7.55 million shares, up from 7.23 million shares in 2017Q3. Also, the number of hedge funds holding Vse Corp in top ten positions was flat from 2 to 2 for the same number . Sold All: 8 Reduced: 28 Increased: 32 New Position: 20.

Investors sentiment increased to 2.25 in Q4 2017. Its up 1.70, from 0.55 in 2017Q3. It is positive, as 2 investors sold Eleven Biotherapeutics, Inc. shares while 2 reduced holdings. 4 funds opened positions while 5 raised stakes. 1.80 million shares or 48.09% more from 1.21 million shares in 2017Q3 were reported. Vanguard reported 326,883 shares or 0% of all its holdings. Northern Tru Corp has invested 0% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Moreover, Citadel has 0% invested in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 15,372 shares. Bank Of New York Mellon Corporation holds 0% or 44,849 shares. Moreover, Royal Fincl Bank Of Canada has 0% invested in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 505 shares. Bridgeway Cap reported 65,000 shares. Geode Management Ltd Liability Corporation invested in 0% or 56,222 shares. Citigroup reported 600 shares stake. Blackrock stated it has 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Morgan Stanley holds 0% or 12,062 shares in its portfolio. Parallax Volatility Advisers Ltd Partnership stated it has 36,761 shares. Fiduciary Tru Com reported 20,000 shares or 0% of all its holdings. The New York-based Two Sigma Secs Limited Company has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Virtu Finance Ltd Llc holds 0.02% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 427,048 shares. Panagora Asset Inc invested in 3,475 shares.

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics . The company has market cap of $66.18 million. It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. It currently has negative earnings. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

Among 3 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Eleven Biotherapeutics had 6 analyst reports since August 15, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Citigroup given on Wednesday, March 16. As per Thursday, April 12, the company rating was maintained by H.C. Wainwright. On Tuesday, January 19 the stock rating was downgraded by Citigroup to “Neutral”. The rating was maintained by Leerink Swann with “Outperform” on Saturday, August 15. The firm has “Market Perform” rating by Leerink Swann given on Tuesday, January 19.

VSE Corporation operates as a diversified services and supply firm in the United States. The company has market cap of $560.59 million. The firm operates through four divisions: Supply Chain Management Group; Aviation Group; Federal Services Group; and IT, Energy and Management Consulting Group. It has a 14.31 P/E ratio. The Supply Chain Management Group segment offers sourcing, acquisition, scheduling, transportation, shipping, logistics, data management, and other services to assist its clients with supply chain management.

The stock increased 0.57% or $0.29 during the last trading session, reaching $51.52. About 8,993 shares traded. VSE Corporation (VSEC) has risen 29.15% since April 17, 2017 and is uptrending. It has outperformed by 17.60% the S&P500.

Koonce Calvin Scott holds 100% of its portfolio in VSE Corporation for 1.85 million shares. Montgomery Investment Management Inc owns 234,320 shares or 4.61% of their US portfolio. Moreover, Hendershot Investments Inc. has 1.36% invested in the company for 69,631 shares. The Florida-based Wilen Investment Management Corp. has invested 0.38% in the stock. Ativo Capital Management Llc, a Illinois-based fund reported 25,408 shares.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: